XML 43 R32.htm IDEA: XBRL DOCUMENT v3.10.0.1
Related Parties Transactions (Details Textual) - USD ($)
1 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended
May 06, 2016
Jun. 27, 2018
Jan. 18, 2018
Sep. 30, 2017
Jul. 24, 2017
Jan. 26, 2017
Sep. 30, 2018
Sep. 30, 2017
Sep. 30, 2018
Sep. 30, 2017
Dec. 31, 2017
May 09, 2018
Sep. 25, 2017
May 26, 2017
Related Parties Transactions (Textual)                            
Amount received from BriVision             $ 4,041,703   $ 4,041,703   $ 4,229,320      
Outstanding loan                 793,000   950,000      
Accrued interest                 25,297   17,460      
Interest expenses             42,851 $ 27,460 114,682 $ 74,960        
Additional paid-in capital             13,909,157   13,909,157   13,805,936      
Monthly base rent                 5,000          
Rent expenses                 0 35,000        
Related party transactions, description       Pursuant to the Investment and Equity Transfer Agreement, Everfront agreed to purchase 2,000,000 common shares of the Company owned by AsianGene at $1.60 per share in a total amount of $3,200,000, of which $160,000 is due before September 15, 2017 and the remaining amount of $3,040,000 is due before December 15, 2017. As of September 30, 2018 and December 31, 2017, Everfront only paid $160,000 to AsianGene. AsianGene also agreed to loan the proceeds to the Company for working capital purpose. On January 16, 2018, AsianGene and the Company entered into a loan agreement. Pursuant to the loan agreement, the loan bears interest at 1% per month (or equivalent to 12% per annum) and the Company is required to pay interest monthly to the lender. The maturity date of this loan is January 15, 2019.                    
Unsecured convertible promissory note [Member]                            
Related Parties Transactions (Textual)                            
Accrued interest                 14,567          
Aggregate principal amount   $ 250,000                   $ 300,000    
Chairman [Member]                            
Related Parties Transactions (Textual)                            
Aggregate working capital                 $ 100   $ 100      
Interest rate percentage                 0.00%   0.00%      
Collaborative Arrangement [Member]                            
Related Parties Transactions (Textual)                            
Amount received from BriVision         $ 3,000,000   100,000,000   $ 100,000,000          
Common stock new issues $ 900,000       $ 3,000,000                  
Due to BioFirst                         $ 3,000,000  
Yuangene Corporation [Member]                            
Related Parties Transactions (Textual)                            
Amount received from BriVision             53,000   53,000   $ 3,000      
Outstanding loan                 50,000   0      
Accrued interest                 4,208   0      
Interest expenses                 4,208 0        
Aggregate working capital     $ 50,000           $ 3,000   $ 3,000      
Interest rate percentage                 0.00%   0.00%      
Related party transactions, description     <p style="margin: 0pt">Under the terms of the loan agreement, the loan bears interest at 1% per month (or equivalent to 12% per annum) and the Company is required to pay interest monthly to the lender. The loan matured on February 1, 2018.</p>                      
Loan Agreement [Member]                            
Related Parties Transactions (Textual)                            
Total commitment           $ 950,000                
Loan maturity date           Feb. 01, 2018                
Loan agreement, description           The loan bears interest at 1% per month (or equivalent to 12% per annum) and the Company is required to pay interest monthly to the lender.                
Asiangene Corporation [Member]                            
Related Parties Transactions (Textual)                            
Amount received from BriVision             160,000   $ 160,000   $ 160,000      
Outstanding loan                 160,000   160,000      
Accrued interest                 9,626   0      
Interest expenses                 13,571 0        
BioLite [Member]                            
Related Parties Transactions (Textual)                            
Aggregate working capital                 $ 21,603   $ 109,220      
Interest rate percentage                 0.00%   0.00%      
ABVC-Rgene Co-development Agreement [Member]                            
Related Parties Transactions (Textual)                            
Amount received from BriVision             450,000   $ 450,000   $ 450,000     $ 3,000,000
Common stock new issues                 2,550,000   2,550,000      
Additional paid-in capital       $ 3,000,000       $ 3,000,000   3,000,000        
BioFirst Corporation [Member]                            
Related Parties Transactions (Textual)                            
Amount received from BriVision             $ 3,807,000   3,807,000   3,957,000      
Interest expenses                 82,336 74,960        
Aggregate working capital                 $ 14,000   $ 7,000      
Interest rate percentage                 0.00%   0.00%      
BioFirst (Australia) Pty Ltd. [Member]                            
Related Parties Transactions (Textual)                            
Aggregate working capital                 $ 40,000          
Interest rate percentage                 0.00%          
Keypoint Technology Ltd [Member] | Unsecured convertible promissory note [Member]                            
Related Parties Transactions (Textual)                            
Amount received from BriVision   $ 250,000                        
Interest expenses                 $ 5,167 $ 0        
Interest rate percentage   8.00%